Impact of nutritional parameter variations during definitive chemoradiotherapy in locally advanced oesophageal cancer
Aude Di Fiore(Centre Hospitalier Universitaire de Rouen), Frédéric Di Fiore(Université Paris Cité), David Sefrioui(Inserm), Ahmed Benyoucef(Université de Rouen Normandie), Valérie Blondin(Université de Rouen Normandie), Pierre Michel(Aix-Marseille Université), Alice Gangloff(Centre Hospitalier Universitaire de Rouen), Olivier Rigal(Centre Henri Becquerel), Martine Quiesse(Université de Rouen Normandie), Stéphane Lecleire(Inserm), Isabelle Iwanicki–Caron(Centre Hospitalier Universitaire de Rouen)
Cited by 32
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial
|The Lancet Oncology|2014|451
The Expression and the Cellular Distribution of the Tight Junction Proteins Are Altered in Irritable Bowel Syndrome Patients With Differences According to the Disease Subtype
|The American Journal of Gastroenterology|2011|290
A neural network algorithm for detection of GI angiectasia during small-bowel capsule endoscopy
|Gastrointestinal Endoscopy|2018|208
Baseline Nutritional Status Is Predictive of Response to Treatment and Survival in Patients Treated by Definitive Chemoradiotherapy for a Locally Advanced Esophageal Cancer
|The American Journal of Gastroenterology|2007|183